The senolytic field progressed with unusual speed from animal model proof-of-concept (2011) to first human trial (2019) to global multi-site trials (2022–2025). The Mayo Clinic has been the primary institutional driver, with collaborating groups at the Scripps Research Institute, University of Texas Health, University of Minnesota, and international partners.

Which institution has contributed most to senolytic research?

The Mayo Clinic Kogod Center on Aging (James Kirkland's lab) has been the most prolific contributor: discovering D+Q senolytic combination, running first human trials, and establishing most of the clinical trial infrastructure for the field.

When might senolytics be commercially available as drugs?

If current Phase 2/3 trials succeed, prescription senolytic drugs could reach FDA approval within 5–10 years. However, fisetin and quercetin are available now as supplements — albeit without FDA drug approval status.